Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Strata Critical Medical (SRTAW) Preferred Stock Liabilities (2019 - 2021)

Historic Preferred Stock Liabilities for Strata Critical Medical (SRTAW) over the last 3 years, with Q1 2021 value amounting to $225.0 million.

  • Strata Critical Medical's Preferred Stock Liabilities fell 1454.49% to $225.0 million in Q1 2021 from the same period last year, while for Mar 2021 it was $225.0 million, marking a year-over-year decrease of 1454.49%. This contributed to the annual value of $226.1 million for FY2020, which is N/A changed from last year.
  • According to the latest figures from Q1 2021, Strata Critical Medical's Preferred Stock Liabilities is $225.0 million, which was down 1454.49% from $226.1 million recorded in Q4 2020.
  • Strata Critical Medical's Preferred Stock Liabilities' 5-year high stood at $263.3 million during Q1 2020, with a 5-year trough of $225.0 million in Q1 2021.
  • Moreover, its 3-year median value for Preferred Stock Liabilities was $262.0 million (2019), whereas its average is $249.9 million.
  • Its Preferred Stock Liabilities has fluctuated over the past 5 years, first soared by 43.99% in 2020, then plummeted by 1454.49% in 2021.
  • Over the past 3 years, Strata Critical Medical's Preferred Stock Liabilities (Quarter) stood at $246.6 million in 2019, then fell by 8.32% to $226.1 million in 2020, then fell by 0.48% to $225.0 million in 2021.
  • Its last three reported values are $225.0 million in Q1 2021, $226.1 million for Q4 2020, and $263.2 million during Q3 2020.